Brief Communication
of these enzymes, while in India, other carbapenemases, in particular NDM-1, have been the most extensively observed carbapenemase in Enterobacteriaceae. [6, 8] Originally found in Shewanella species, OXA-48-like carbapenemases have now emerged in Enterobacteriaceae, predominantly K. pneumoniae and EC, and the level of resistance to carbapenems is usually higher when ESBL and permeability defects are associated. [9] OXA-181, a variant of OXA-48, was initially reported in India but has been sporadically detected in the United Kingdom, The Netherlands, France, New Zealand, Oman and Singapore. [10, 11] A previous study (January-June 2008) had documented a prevalence of 10.6% and 8.8% of CRE and carbapenemase production, respectively, in our institute by phenotypic methods. [12] Given the variation in the distribution of carbapenemases found in different geographical regions from time to time, we aimed to perform molecular identification of carbapenemase production in CRE which is the reference standard for identifying carbapenemase-producing CRE. [7, 8] The objectives of this study were: (i) to determine the proportion of CRE among Enterobacteriaceae bloodstream isolates, (ii) to compare the antibiogram of CRE with non-CRE isolates and (iii) to determine the distribution of selected carbapenemase-encoding genes among CRE.
Methods

Study setting
The study, approved by the Institutional Ethical Committee, was conducted at the Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, a 1531-bedded tertiary care, teaching and referral hospital in North India over a 3-year period from January 2011 to December 2013.
Bacterial isolates
Consecutive, non-duplicate isolates of EC and K. pneumoniae obtained from patients with clinically diagnosed BSIs admitted to the various wards of the hospital were included in the study. Organism identification was performed by the standard microbiological techniques, including characteristic appearance on culture media, Gram staining reaction and pattern of biochemical profiles. [13] Antimicrobial susceptibility testing Antimicrobial susceptibility testing and interpretation were carried out on Mueller-Hinton agar (HiMedia, Mumbai, India) by the disk-diffusion method as per the Clinical and Laboratory Standards Institute guidelines using disks of standard concentration (HiMedia, Mumbai, India). [14] Minimum inhibitory concentration (MIC) was determined for ETP, MEM and IPM by Etest (bioMérieux, Marcy l'Etoile, France). Standard strains of EC ATCC 25922, Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 27853 were used as controls.
Detection of carbapenemase-encoding genes
Carbapenemase-encoding genes in the CRE isolates were amplified using a panel of primers (Sigma-Aldrich Ltd) with their expected amplicon sizes as listed in Table 1 with single polymerase chain reactions (PCRs) for each gene. [15] [16] [17] [18] Control strains used were K. pneumoniae ATCC BAA 1705 (bla KPC positive) and K. pneumoniae ATCC BAA 2156 (bla NDM positive).
results
During the study period, 387 isolates were recovered comprising of 214 K. pneumoniae (55.3%) and 173 EC (44.7%), of which 44 were from neonatal, 138 from paediatric, 128 from intensive care and 77 from adult medical units. A total of 93 (24.03%) isolates were found to be CRE (59 K. pneumoniae and 34 EC). All (100%) of CRE were ERT resistant, 65 (69.9%) MEM resistant and 51 (54.8%) IPM resistant. Table 2 shows the overall resistance of the isolates to the antibiotics tested as well as the comparative antibiogram between the CRE and non-CRE isolates, revealing significantly higher resistance to antibiotics in CRE as compared to non-CRE isolates. 
dIscussIon
The earliest reports of carbapenemase-mediated resistance in Enterobacteriaceae from India consist of NDM-1 producing Enterobacteriaceae from Mumbai in 2010 [19] and dissemination of both NDM-1 and OXA-181 producing Enterobacteriaceae collected from various Indian hospitals during 2006 and 2007. [10] In the former study, of 24 CRE recovered from a tertiary hospital, 22 were found to be harbouring NDM-1 gene (10 were Klebsiella spp., 9 EC, 2 Enterobacter spp. and 1 Morganella morganii). [19] In the latter study, among 39 CRE (2.7% overall; EC, Enterobacter cloacae and K. pneumoniae strains) isolated in 2006 and 2007 in India, 15 strains carried bla NDM-1 and 10 harboured bla OXA-181 . [10] Subsequent reports revealed an increasing prevalence and dissemination of NDM-1β-lactamase, often in conjunction with other carbapenemase genes such as bla OXA-48 , bla KPC and bla VIM in various combinations, [20] [21] [22] as has been observed in the present study.
The current study (2011-2013) showed a prevalence of 24.03% carbapenem resistance amongst Enterobacteriaceae bloodstream isolates in our institute, which is more than twice the prevalence (10.6%) compared to our earlier study performed 3 years prior in 2008. [12] Similarly, a study on neonatal septicaemia has reported an increase in CRE from 11% in 2008 to 37.5% in 2011. [23] Elsewhere, the prevalence of carbapenem-resistant K. pneumoniae has been found to vary from 4.05% in Malaysia to 5%, 8% and 13% in Argentina, USA and Greece, respectively. [24] Overall, carbapenemase-mediated resistance was identified in 71 (76.3%) CRE isolates with the highest prevalence conferred by NDM-1 genes, followed by OXA-48 and OXA-181 in our setting. Co-occurrence of multiple carbapenemase genes was found in 39.4% isolates. In contrast, in a recent study conducted by the Centers for Disease Control and Prevention, USA, on a collection of CRE isolates (January 2011-January 2014) from different participating centres, only 30% (94/312) of CRE had carbapenemase genes with majority as KPC (93%-100%) and few as NDM (6%-7%). [25] However, another study during the same time period in Los Angeles, California, from 2011 to 2013 showed a higher proportion of carbapenemase-encoding genes in CRE (81.7%, 94/115) and included bla KPC (78.3%), bla NDM-1 ( 0.9%) and bla SME (2.6%). [26] Elsewhere, the proportion of carbapenemase-encoding genes in CRE have been reported to vary from 60.8% in China [27] to 77.3% in Sultanate of Oman [28] and 98% in Turkey, [29] with multiple genes detected in 10%, 5.9% and 13% of the carbapenemase-positive isolates, respectively. The predominant genes have been KPC-2 (54.9%), [27] NDM (50%) [28] and OXA-48 (86%) [29] in these studies.
Imipenem (MIC 50 1.5 µg/ml) had better activity than meropenem (MIC 50 3 µg/ml) against ertapenem-non-susceptible Enterobacteriaceae isolates in the current study with 65 (69.9%) MEM-resistant compared to 51 (54.8%) IPM-resistant isolates. However, susceptibility to both [30] These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by carbapenem-non-susceptible Enterobacteriaceae isolates.
conclusIon
Our study identified the presence of carbapenemase-mediated resistance in a large proportion of CRE isolates. Delineation of resistance mechanisms is important in view of future therapeutics concerned with the treatment of CRE (e.g. using carbapenems in combination with carbapenemase-inhibitors for the treatment of carbapenemase-producing isolates) and for aiding control efforts by surveillance and infection control interventions. 
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